(Circulation. 1999;100:547-552.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Interindividual Heterogeneity in the Hypoxic Regulation of VEGF
Significance for the Development of the Coronary Artery Collateral Circulation
From the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology (A.S., L.L., I.H., R.B., T.S., K.S., P.L., A.P.L.), and the Departments of Cardiology (R.B.), Medicine (A.R.), and Nephrology (K.S.), Rambam Medical Center, Haifa, Israel.
Correspondence to Dr Andrew P. Levy, Rappaport Faculty of Medicine, POB 9649, Bat Galim, Israel. E-mail alevy{at}tx.technion.ac.il
Background—The coronary artery collateral circulation may be beneficial in protecting against myocardial ischemia and necrosis. However, there is a tremendous interindividual variability in the degree of new collateral formation in patients with coronary artery disease. The basis for this interindividual heterogeneity is not understood. In this study we test the hypothesis that failure to generate collateral vessels is associated with a failure to appropriately induce with hypoxia or ischemia the angiogenic factor, vascular endothelial growth factor (VEGF).
Methods and Results—We correlated the VEGF response to hypoxia in the monocytes harvested from patients with coronary artery disease with the presence of collaterals visualized during routine angiography. We found that there was a highly significant difference in the hypoxic induction of VEGF in patients with no collaterals compared with patients with some collaterals (mean fold induction 1.9±0.2 versus 3.2±0.3, P<0.0001). After subjecting the data to ANCOVA, using as covariates a number of factors that might influence the amount of collateral formation (ie, age, sex, diabetes, smoking, hypercholesterolemia), patients with no collaterals still have a significantly lower hypoxic induction of VEGF than patients with collaterals.
Conclusions—This study provides evidence in support of the hypothesis that the ability to respond to progressive coronary artery stenosis is strongly associated with the ability to induce VEGF in response to hypoxia. The observed interindividual heterogeneity in this response may be due to environmental, epigenetic, or genetic causes. This interindividual heterogeneity may also help to explain the variable angiogenic responses seen in other conditions such as diabetic retinopathy and solid tumors.
Key Words: collateral circulation • angiogenesis • ischemia • hypoxia • growth substances
This article has been cited by other articles:
 |
|
 |
|
  L. Jain, C. A. Vargo, R. Danesi, T. M. Sissung, D. K. Price, D. Venzon, J. Venitz, and W. D. Figg The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors Mol. Cancer Ther., September 1, 2009; 8(9): 2496 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dieleman, A.-M. Sauer, C. Klijn, H. Nathoe, K. Moons, C. Kalkman, J. Kappelle, and D. Van Dijk Presence of coronary collaterals is associated with a decreased incidence of cognitive decline after coronary artery bypass surgery Eur. J. Cardiothorac. Surg., January 1, 2009; 35(1): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. S. Brooks, G. P. Elvidge, L. Glenny, J. M. Gleadle, C. Liu, J. Ragoussis, T. G. Smith, N. P. Talbot, L. Winchester, P. H. Maxwell, et al. Variations within oxygen-regulated gene expression in humans J Appl Physiol, January 1, 2009; 106(1): 212 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Kinnaird, E. Stabile, S. Zbinden, M.-S. Burnett, and S. E. Epstein Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions Cardiovasc Res, May 1, 2008; 78(2): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Lin, W. H.-H. Sheu, W.-J. Lee, Y.-T. Chen, T.-J. Liu, C.-T. Ting, and W.-L. Lee Circulating Hepatocyte Growth Factor Level but Not Basic Fibroblast Growth Factor Level Is Elevated in Angiography-Proven Symptomatic Peripheral Artery Disease Angiology, September 1, 2007; 58(4): 420 - 428. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Chalothorn, J. A. Clayton, H. Zhang, D. Pomp, and J. E. Faber Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains Physiol Genomics, July 18, 2007; 30(2): 179 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Chittenden, J. A. Sherman, F. Xiong, A. E. Hall, A. A. Lanahan, J. M. Taylor, H. Duan, J. D. Pearlman, J. H. Moore, S. M. Schwartz, et al. Transcriptional Profiling in Coronary Artery Disease: Indications for Novel Markers of Coronary Collateralization Circulation, October 24, 2006; 114(17): 1811 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W.Y. Chung, Y. N. Hsiang, L. A. Matzke, B. M. McManus, C. van Breemen, and E. B. Okon Reduced Expression of Vascular Endothelial Growth Factor Paralleled With the Increased Angiostatin Expression Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in Human Type 2 Diabetic Arterial Vasculature Circ. Res., July 21, 2006; 99(2): 140 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Prior, J. M. Hagberg, C. M. Paton, L. W. Douglass, M. D. Brown, J. C. McLenithan, and S. M. Roth DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1848 - H1855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Doi, E. Noiri, A. Nakao, T. Fujita, S. Kobayashi, and K. Tokunaga Functional Polymorphisms in the Vascular Endothelial Growth Factor Gene Are Associated with Development of End-Stage Renal Disease in Males J. Am. Soc. Nephrol., March 1, 2006; 17(3): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H Maxwell Hypoxia-inducible factor as a physiological regulator Exp Physiol, November 1, 2005; 90(6): 791 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons Angiogenesis: Where Do We Stand Now? Circulation, March 29, 2005; 111(12): 1556 - 1566. [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Unthank, K. M. Sheridan, and M. C. Dalsing Collateral Growth in the Peripheral Circulation: A Review Vascular and Endovascular Surgery, July 1, 2004; 38(4): 291 - 313. [Abstract] [PDF]
|
|
|
|
|
|
A. Roguin, J. R. Resar, J. Koerselman, Y. van der Graaf, P. P.T. de Jaegere, and D. E. Grobbee Genetics and Susceptibility of Coronary Collateral Formation * Response Circulation, November 25, 2003; 108 (21): e149 - e149. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lenihan, A. Osman, V. Sriram, J. Aitsebaomo, and C. Patterson Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1507 - H1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Bradley and J. S. Floras Sleep Apnea and Heart Failure: Part I: Obstructive Sleep Apnea Circulation, April 1, 2003; 107(12): 1671 - 1678. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishida, T.-S. Li, K. Hirata, M. Yano, M. Matsuzaki, and K. Hamano Improvement of cardiac function by bone marrow cell implantation in a rat hypoperfusion heart model Ann. Thorac. Surg., March 1, 2003; 75(3): 768 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stevens, J. Soden, P. E. Brenchley, S. Ralph, and D. W. Ray Haplotype Analysis of the Polymorphic Human Vascular Endothelial Growth Factor Gene Promoter Cancer Res., February 15, 2003; 63(4): 812 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lavie, H. Kraiczi, A. Hefetz, H. Ghandour, A. Perelman, J. Hedner, and P. Lavie Plasma Vascular Endothelial Growth Factor in Sleep Apnea Syndrome: Effects of Nasal Continuous Positive Air Pressure Treatment Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1624 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.M. Cotton, A. Mathur, Y. Hong, A.S. Brown, J.F. Martin, and J.D. Erusalimsky Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery Eur. Heart J., June 2, 2002; 23(12): 953 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Chou, I. Suzuma, K. J. Way, D. Opland, A. C. Clermont, K. Naruse, K. Suzuma, N. L. Bowling, C. J. Vlahos, L. P. Aiello, et al. Decreased Cardiac Expression of Vascular Endothelial Growth Factor and Its Receptors in Insulin-Resistant and Diabetic States: A Possible Explanation for Impaired Collateral Formation in Cardiac Tissue Circulation, January 22, 2002; 105(3): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. SCHULZ, C. HUMMEL, S. HEINEMANN, W. SEEGER, and F. GRIMMINGER Serum Levels of Vascular Endothelial Growth Factor Are Elevated in Patients with Obstructive Sleep Apnea and Severe Nighttime Hypoxia Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 67 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Tabibiazar and S.G Rockson Angiogenesis and the ischaemic heart Eur. Heart J., June 1, 2001; 22(11): 903 - 918. [PDF]
|
|
|
|
 |
|
 Y. Dor, R. Porat, and E. Keshet Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1367 - C1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H1923 - H1927. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Post, R. Laham, F. W. Sellke, and M. Simons Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc Res, February 16, 2001; 49(3): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons, R. O. Bonow, N. A. Chronos, D. J. Cohen, F. J. Giordano, H. K. Hammond, R. J. Laham, W. Li, M. Pike, F. W. Sellke, et al. Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus : An Expert Panel Summary Circulation, September 12, 2000; 102 (11): e73 - e86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Semenza HIF-1 and human disease: one highly involved factor Genes & Dev., August 15, 2000; 14(16): 1983 - 1991. [Full Text]
|
|